| Literature DB >> 29110035 |
J Lüke1, M Hasenfratz1, P Möller1, T F E Barth2.
Abstract
A giant cell tumor of bone (GCTB) is one of the giant cell-rich lesions of bone and has to be differentiated from non-ossifying fibroma, aneurysmatic bone cyst, chondroblastoma, "brown tumor" and osteosarcoma containing giant cells. A hallmark of GCTB is the presence of the distinct histone 3 (H3F3A) mutation G34W and its detection either by sequencing methods or using immunohistochemistry with a novel antibody against this mutational site. Worrisome is the fact that under denosumab therapy a histological change of the lesions can be seen and there are first reports of sarcomas arising after therapy. When diagnosing giant cell-rich lesions, pathologists should be aware of the various differential diagnoses and morphological spectrum within GCTB.Entities:
Keywords: Denosumab; Differential diagnosis; Giant cell rich lesions; H3F3A mutation; Histone 3
Mesh:
Substances:
Year: 2018 PMID: 29110035 DOI: 10.1007/s00292-017-0391-9
Source DB: PubMed Journal: Pathologe ISSN: 0172-8113 Impact factor: 1.011